Business Context and Reporting Period
Company: CURIS, INC. (CRIS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Curis is a biotechnology company focused on developing emavusertib (CA-4948), an IRAK4 inhibitor for hematologic malignancies. The company also holds a collaboration with Genentech/Roche for Erivedge royalties, though a significant portion of these royalties is pledged to Oberland Capital Management under a royalty purchase agreement.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenues, net | $3,176 | $2,931 | $8,305 | $7,563 |
| Net Loss | $(7,729) | $(10,092) | $(26,938) | $(33,771) |
| Net Loss Per Share (Basic/Diluted) | $(0.49) | $(1.70) | $(2.19) | $(5.77) |
| Cash and Cash Equivalents (Sep 30, 2025) | $9,051 | |||
| Total Liabilities (Sep 30, 2025) | $42,332 | |||
| Stockholders' Deficit (Sep 30, 2025) | $(14,691) | |||
| Cash Used in Operating Activities (9M) | $(20,830) | $(30,303) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 8% in Q3 2025 and 10% for the nine months ended September 30, 2025, compared to the prior year periods, driven by royalties from Erivedge sales.
- Expense Reduction: Research and development (R&D) expenses decreased 34% in Q3 and 24% for the nine months, primarily due to lower clinical, employee-related, and consulting costs. General and administrative (G&A) expenses decreased 3% in Q3 and 17% for the nine months.
- Net Loss Improvement: Net loss narrowed by 23% in Q3 and 20% for the nine months compared to the prior year, reflecting reduced operating expenses.
- Financing Activity: The company raised approximately $15.5 million in net proceeds from equity offerings in March and July 2025 (common stock, pre-funded warrants, and common warrants).
- Liquidity Decline: Cash and cash equivalents decreased from $19.9 million at year-end 2024 to $9.1 million at September 30, 2025.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
Management has identified conditions raising substantial doubt about the company's ability to continue as a going concern. With $9.1 million in cash, the company expects to fund operations only into the first quarter of 2026. Substantial additional capital is required immediately to continue the emavusertib development program.
Subsequent Event: Sale of Royalty Subsidiary
On November 6, 2025, the company sold its interest in Curis Royalty LLC (including Erivedge IP and the Genentech collaboration) to TPC Investments Royalty LLC (Oberland) for $2.5 million upfront. This transaction extinguishes the liability related to the sale of future royalties (approx. $28.6 million carrying value) and will result in a gain in Q4 2025. Following this sale, Curis will no longer receive Erivedge royalties.
Nasdaq Compliance
The company is not in compliance with Nasdaq's Minimum Market Value of Listed Securities (MVLS) requirement ($35 million). It received an exemption until November 14, 2025, to regain compliance. Failure to comply could result in delisting.
Regulatory and Trade Risks
Risks include potential FDA disruptions due to government shutdowns and workforce reductions, as well as trade policy uncertainties involving tariffs on pharmaceutical imports from China and Canada, which could impact supply chains and costs.
Investor Verification Checklist
- Cash Runway: Verify the timeline for raising additional capital, as current cash reserves are insufficient beyond Q1 2026.
- Subsequent Event Impact: Confirm the accounting treatment and timing of the gain from the sale of Curis Royalty LLC and the cessation of Erivedge royalty revenue.
- Nasdaq Status: Monitor the company's ability to regain compliance with Nasdaq listing requirements by the November 14, 2025 deadline.
- Emavusertib Progress: Review upcoming clinical data releases for the TakeAim Lymphoma and Leukemia studies, which are critical for future valuation.
- Debt Obligations: Assess the impact of the extinguished royalty liability on the balance sheet and future cash flow obligations.